Search Result

Results for "

osteoarthritis pain

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Adenosine Receptor (1) Amylin Receptor (1) Biochemical Assay Reagents (1) Cannabinoid Receptor (1) CGRP Receptor (1) Collagen (1) COX (17) Cytochrome P450 (2) EGFR (1) ERK (2) Isotope-Labeled Compounds (3) Melanocortin Receptor (2) MMP (1) Neurokinin Receptor (1) NO Synthase (1) PGE synthase (5) Phosphodiesterase (PDE) (2) Prostaglandin Receptor (4) Reference Standards (6) ROCK (2) TGF-β Receptor (1) TNF Receptor (1) Trk Receptor (4) TRP Channel (2)
By Research Areas:	Cancer (9) Infection (3) Inflammation/Immunology (39) Metabolic Disease (3) Neurological Disease (19)

By Targets:

Adenosine Receptor (1)

Amylin Receptor (1)

Biochemical Assay Reagents (1)

Cannabinoid Receptor (1)

CGRP Receptor (1)

Collagen (1)

COX (17)

Cytochrome P450 (2)

EGFR (1)

ERK (2)

Isotope-Labeled Compounds (3)

Melanocortin Receptor (2)

MMP (1)

Neurokinin Receptor (1)

NO Synthase (1)

PGE synthase (5)

Phosphodiesterase (PDE) (2)

Prostaglandin Receptor (4)

Reference Standards (6)

ROCK (2)

TGF-β Receptor (1)

TNF Receptor (1)

Trk Receptor (4)

TRP Channel (2)

By Research Areas:

Cancer (9)

Infection (3)

Inflammation/Immunology (39)

Metabolic Disease (3)

Neurological Disease (19)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Isotope-Labeled Compounds

Cat. No.	상품명	Target	연구분야	Chemical Structure

HY-D0849

Sodium iodoacetate 2 Publications Verification Iodoacetic acid sodium salt	Biochemical Assay Reagents	Metabolic Disease Inflammation/Immunology
Sodium iodoacetate is a specific inhibitor of GAPDH and has glycolysis inhibitory activity. In addition, sodium iodoacetate can induce osteoarthritis and related pain models in experimental animals .

HY-P99221

Tanezumab RN-624; PF 4383119	Trk Receptor	Neurological Disease Inflammation/Immunology Cancer
Tanezumab (RN-624) is a humanized anti-NGF mAb with high affinity and specificity. Tanezumab blocks NGF binding to its receptors, p75 and TrkA, in the peripheral nervous system. Tanezumab can be used in studies of acute and chronic pain such as osteoarthritis, knee and neuralgia, as well as post-herpetic neuralgia .

HY-P99297

Bedinvetmab ZTS-00508841	Trk Receptor	Inflammation/Immunology
Bedinvetmab (ZTS-00508841) is a canine monoclonal antibody (mAb) targeting nerve growth factor (NGF). Bedinvetmab inhibits NGF interaction with tropomyosin receptor kinase A (trkA) and p75 neurotrophin receptor (p75NTR) receptors. Bedinvetmab can be used for the research of osteoarthritis pain in dogs .

HY-B1456A

Fenoprofen 2 Publications Verification LILLY-53858	COX Melanocortin Receptor ERK	Inflammation/Immunology
Fenoprofen (LILLY-53858) is a nonsteroidal anti-inflammatory agent (NSAID) and inhibits cyclooxygenase (COX). Fenoprofen is a melanocortin receptors (MCRs) positive allosteric modulator (PAM). Fenoprofen also increases ERK1/2 activation in HEK293T cells. Fenoprofen has anti-arthritic activities and can be used for the study of rheumatoid arthritis and osteoarthritis .

HY-17474

Parecoxib 5 Publications Verification SC 69124	COX	Infection Neurological Disease Inflammation/Immunology Cancer
Parecoxib (SC 69124) is a highly selective and orally active COX-2 inhibitor that is permeable to the blood-brain barrier, the proagent of Valdecoxib (HY-15762). Parecoxib Sodium is a nonsteroidal anti-inflammatory agent (NSAID) and inhibits prostaglandin (PG) synthesis. Parecoxib can be used for the relief of acute postoperative pain and symptoms of chronic inflammatory conditions such as osteoarthritis and rheumatoid arthritis in vivo.

HY-171846

LY3526318	TRP Channel	Neurological Disease Inflammation/Immunology
LY3526318 is an orally active, selective TRPA1 antagonist (IC₅₀=5-6μM). LY3526318 blocks TRPA1 channels, inhibits pain signal transduction mediated by the channel, and exerts analgesic activity. LY3526318 is mainly used in the research of chronic pain-related fields, such as diabetic peripheral neuropathy, chronic low back pain, and pain caused by osteoarthritis .

HY-P99627

Frunevetmab NV-02; PG110; ABT-110	Trk Receptor	Inflammation/Immunology
Frunevetmab (NV-02) is a felinized anti-nerve growth factor (NGF) monoclonal antibody with a K_d of 20 pM. Frunevetmab can effectively decrease osteoarthritis (OA) pain in cats .

HY-W009706

Alclofenac Allopydin; W-7320	Prostaglandin Receptor	Neurological Disease Inflammation/Immunology
Alclofenac (Allopydin) is an orally active prostaglandin synthase inhibitor with anti-inflammatory, analgesic and antipyretic activities. Alclofenac irreversibly inhibits platelet aggregation. Alclofenac can be used in research related to rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, low back pain and sciatica .

HY-B0890

Zomepirac sodium salt McN-2783-21-98	PGE synthase	Neurological Disease Inflammation/Immunology
Zomepirac sodium salt (McN-2783-21-98) is an orally active prostaglandin synthetase inhibitor. Zomepirac sodium salt blocks prostaglandin synthesis and inhibits Collagen (HY-P72147)- or Epinephrine (HY-B0447)-induced platelet aggregation. Zomepirac sodium salt can be used for the research of postoperative pain and osteoarthritis .

HY-139589

Zaloglanstat ISC-27864; GRC-27864	PGE synthase COX Collagen	Neurological Disease Inflammation/Immunology
Zaloglanstat (ISC-27864; GRC-27864) is a selective, orally active microsomal mPGES-1 inhibitor. Zaloglanstat has an IC₅₀ of 5 nM for human mPGES-1 without significant inhibitory effect on COX-1/2 (IC₅₀ >10 μM). Zaloglanstat blocks the conversion of arachidonic acid metabolite prostaglandin PGH₂ to prostaglandin PGE₂, thereby inhibiting inflammation-related PGE₂ overproduction and reducing inflammatory responses and pain. Zaloglanstat inhibits IL-1β-induced PGE₂ release in A549 cells and human synovial fibroblasts in vitro. Zaloglanstat inhibits PGE2 release in pig and dog whole blood with IC₅₀s ??of 161 nM and 154 nM, respectively. Zaloglanstat can be used in the study of asthma, osteoarthritis, and neurodegenerative diseases .

HY-108519

AS1892802	ROCK	Neurological Disease
AS1892802 is a potent, orally active, and highly selective inhibitor of ROCK. The onset of antinociceptive effect of AS1892802 is as fast as those of Tramadol and Diclofenac. AS1892802 did not induce gastric irritation or abnormal behavior. AS1892802 is an attractive analgesic profile for the research of severe osteoarthritis pain .

HY-17474A

Parecoxib Sodium 5 Publications Verification SC 69124A	COX	Infection Neurological Disease Inflammation/Immunology Cancer
Parecoxib Sodium (SC 69124A) is a highly selective and orally active COX-2 inhibitor that is permeable to the blood-brain barrier, the proagent of Valdecoxib (HY-15762). Parecoxib Sodium is a nonsteroidal anti-inflammatory agent (NSAID) and inhibits prostaglandin (PG) synthesis. Parecoxib Sodium can be used for the relief of acute postoperative pain and symptoms of chronic inflammatory conditions such as osteoarthritis and rheumatoid arthritis in vivo.

HY-P990071

Fepixnebart LY-3016859	EGFR	Neurological Disease Metabolic Disease Inflammation/Immunology
Fepixnebart (LY3016859) is a humanized monoclonal hIgG4 antibody, which binds and neutralizes only TGFα and epiregulin with high affinity. Fepixnebart can be used for the study of diabetic nephropathy and broad-spectrum chronic pain, including diabetic peripheral neuropathic pain (DPNP), signs and symptoms of osteoarthritis (OA), and chronic low back pain (CLBP) .

HY-122624

MMP13-IN-2	MMP	Inflammation/Immunology
MMP13-IN-2 is a potent, selective and orally active MMP-13 inhibitor. MMP13-IN-2 exhibits excellent potency for MMP-13 (IC₅₀=0.036 nM) and selectivities (greater than 1,500-fold) over MMP-1, 3, 7, 8, 9, 14, and TACE. MMP13-IN-2 has the ability to block the release of collagen from cartilage in vitro. MMP13-IN-2 has the potential for collagenase related disease research .

HY-109547

Diclofenac epolamine Diclofenac hydroxyethylpyrrolidine	COX	Inflammation/Immunology Cancer
Flector Patch (Diclofenac epolamine) is a non-steroidal anti-inflammatory drug (NSAID) . Flector Patch is used for relieving arthritis Pain, acute Pain, osteoarthritis, and actinic Keratosis. Flector Patch has good skin absorption characteristics without local adverse reactions and allergies .

HY-14900

Tedalinab 1 Publications Verification GRC-10693	Cannabinoid Receptor	Inflammation/Immunology
Tedalinab (GRC-10693) is a potent, orally active, and selective cannabinoid receptor 2 (CB2) agonist. Tedalinab has >4700-fold functional selectivity for CB2 over CB1. Tedalinab has potential for neuropathic pain and osteoarthritis treatment .

HY-19665

Lanepitant LY303870	Neurokinin Receptor	Neurological Disease Inflammation/Immunology
Lanepitant (LY303870) is a selective neurokinin-1 (NK-1) receptor antagonist. Lanepitant blocks neurogenic inflammation and pain transmission by preventing the binding of substance P to NK-1 receptors on both neuronal and non-neuronal tissues. Lanepitant can be used to study osteoarthritis .

HY-107320

Amtolmetin guacil	Prostaglandin Receptor COX NO Synthase	Inflammation/Immunology
Amtolmetin guacil is an effective nonsteroidal anti-Inflammatory agent with pain-relieving effects. Amtolmetin guacil inhibits prostaglandin synthesis and cyclooxygenase (COX). Amtolmetin guacil can stimulate capsaicin receptors present on the gastrointestinal wall and also releases gastroprotective nitric oxide (NO). Amtolmetin guacil can be used to research knee osteoarthritis .

HY-100516

Cimicoxib UR-8880	COX Cytochrome P450	Inflammation/Immunology
Cimicoxib (UR-8880) is an orally active, blood-brain barrier-permeable COX-2 inhibitor that also exerts targeted inhibition on CYP2D15. It has an IC₅₀ of 66 nM against hCOX-2, an IC₅₀ of 1.6 μM against canine CYP2D15, and an IC₅₀ of 0.056 μM against feline CYP2D15. By inhibiting the COX-2 pathway to reduce the production of thromboxane B2 and prostaglandin E2, Cimicoxib exerts antipyretic, anti-inflammatory and analgesic effects. Cimicoxib is metabolized by CYP2D15 to form demethyl-cimicoxib, undergoes glucuronidation via UDP-glucuronosyltransferases, and exhibits biphasic elimination kinetics in beagle dogs. Cimicoxib is widely used in studies of inflammatory diseases, osteoarthritis, and perioperative pain associated with orthopedic or soft tissue surgeries .

HY-P991324

MEDI-7352	Trk Receptor TNF Receptor	Inflammation/Immunology
MEDI-7352 is a human bispecific antibody (bsAb) targeting NGF/bNGF & TNF. MEDI-7352 can be used in osteoarthritis (OA) pain research .

HY-119912

Antrafenine dihydrochloride Stakane dihydrochloride	COX	Neurological Disease Inflammation/Immunology
Antrafenine (Stakane) dihydrochloride is a non-narcotic analgesic. Antrafenine dihydrochloride demonstrates central analgesic effects in acetic acid writhing test and mouse hot plate test experiments. Antrafenine dihydrochloride significantly alleviates osteoarthritis pain. Antrafenine dihydrochloride exhibits mild anti-inflammatory activity in a rat toe edema model. Antrafenine dihydrochloride can be used for pain and anti-inflammatory research .

HY-Z7640

4-Desmethyl-2-methyl celecoxib	COX	Inflammation/Immunology
4-Desmethyl-2-methyl celecoxib (Compound 1g) is an orally active and selective Cyclooxygenase-2 (COX-2) inhibitor with an IC₅₀ value of 0.069 μM. 4-Desmethyl-2-methyl celecoxib shows anti-inflammatory, analgesic, and antipyretic activities. 4-Desmethyl-2-methyl celecoxib can reduces the synthesis of prostaglandins. 4-Desmethyl-2-methyl celecoxib is promising for research of inflammatory diseases and pain-related diseases, such as rheumatoid arthritis and osteoarthritis .

HY-114023

BML-288	Phosphodiesterase (PDE)	Neurological Disease
BML-288 (compound Oxindole 1) is a potent PDE2 inhibitor with an IC₅₀ value of 40 nM. BML-288 has the potential for the research of osteoarthritis pain .

HY-17474AR

Parecoxib Sodium (Standard) SC 69124A (Standard)	Reference Standards COX	Inflammation/Immunology Cancer
Parecoxib (Sodium) (Standard) is the analytical standard of Parecoxib (Sodium). This product is intended for research and analytical applications. Parecoxib Sodium (SC 69124A) is a highly selective and orally active COX-2 inhibitor, the proagent of Valdecoxib (HY-15762). Parecoxib Sodium is a nonsteroidal anti-inflammatory agent (NSAID) and inhibits prostaglandin (PG) synthesis. Parecoxib Sodium can be used for the relief of acute postoperative pain and symptoms of chronic inflammatory conditions such as osteoarthritis and rheumatoid arthritis in vivo.

HY-17474R

Parecoxib (Standard) SC 69124 (Standard)	Reference Standards COX	Inflammation/Immunology Cancer
Parecoxib (Standard) is the analytical standard of Parecoxib. This product is intended for research and analytical applications. Parecoxib (SC 69124) is a highly selective and orally active COX-2 inhibitor, the proagent of Valdecoxib (HY-15762). Parecoxib Sodium is a nonsteroidal anti-inflammatory agent (NSAID) and inhibits prostaglandin (PG) synthesis. Parecoxib can be used for the relief of acute postoperative pain and symptoms of chronic inflammatory conditions such as osteoarthritis and rheumatoid arthritis in vivo.

HY-P99748

Nadecnemab	TGF-β Receptor	Inflammation/Immunology
Nadecnemab is an IgG4κ antibody targeting to GFRA3, glial cell derived neurotrophic factor family receptor alpha 3. Nadecnemab can be used for research of osteoarthritis of the knee/pain .

HY-123637

Autotaxin-IN-1	Phosphodiesterase (PDE)	Inflammation/Immunology
Autotaxin-IN-1 is a potent autotaxin inhibitor, which has favorable potency (IC₅₀=2.2 nM), PK properties, and a robust PK/PD relationship. Autotaxin-IN-1 is used in treatment of osteoarthritis pain .

HY-W009706A

Alclofenac sodium Allopydin sodium; W-7320 sodium	Prostaglandin Receptor	Neurological Disease Inflammation/Immunology
Alclofenac (Allopydin) sodium is an orally active prostaglandin synthase inhibitor with anti-inflammatory, analgesic and antipyretic activities. Alclofenac sodium irreversibly inhibits platelet aggregation. Alclofenac can be used in research related to rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, low back pain and sciatica .

HY-W009706B

Alclofenac (lysinate) Allopydin (lysinate); W-7320 (lysinate)	Prostaglandin Receptor	Neurological Disease Inflammation/Immunology
Alclofenac (Allopydin) lysinate is an orally active prostaglandin synthase inhibitor with anti-inflammatory, analgesic and antipyretic activities. Alclofenac lysinate irreversibly inhibits platelet aggregation. Alclofenac lysinate can be used in research related to rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, low back pain and sciatica .

HY-B0890A

Zomepirac McN-2783-21-98 free acid	PGE synthase	Neurological Disease Inflammation/Immunology
Zomepirac (McN-2783-21-98 free acid) is an orally active prostaglandin synthetase inhibitor. Zomepirac blocks prostaglandin synthesis and inhibits Collagen (HY-P72147)- or Epinephrine (HY-B0447)-induced platelet aggregation. Zomepirac can be used for the research of postoperative pain and osteoarthritis .

HY-17474S

Parecoxib-d3 SC 69124-d₃	Isotope-Labeled Compounds COX	Inflammation/Immunology Cancer
Parecoxib-d3 is the deuterium labeled Parecoxib. Parecoxib (SC 69124) is a highly selective and orally active COX-2 inhibitor, the proagent of Valdecoxib (HY-15762). Parecoxib Sodium is a nonsteroidal anti-inflammatory agent (NSAID) and inhibits prostaglandin (PG) synthesis. Parecoxib can be used for the relief of acute postoperative pain and symptoms of chronic inflammatory conditions such as osteoarthritis and rheumatoid arthritis in vivo.

HY-15321A

Etoricoxib hydrochloride MK-0663 hydrochloride; L-791456 hydrochloride	COX	Inflammation/Immunology
Etoricoxib hydrochloride (MK-0663 hydrochloride) is a synthetic nonsteroidal anti-inflammatory drug with cyclooxygenase-2 inhibitory activity. Etoricoxib hydrochloride can inhibit the conversion of arachidonic acid to prostaglandins, thereby reducing inflammation and pain. Etoricoxib hydrochloride is used to inhibit osteoarthritis and has anti-inflammatory and bone remodeling effects. The formulation of etoricoxib hydrochloride is prepared by emulsion solvent evaporation technology and exhibits good cell compatibility and enhanced alkaline phosphatase activity .

HY-17474AS

Parecoxib-d5 sodium SC 69124A-d₅	Isotope-Labeled Compounds COX	Inflammation/Immunology Cancer
Parecoxib-d₅ sodium is the deuterium labeled Parecoxib sodium. Parecoxib Sodium (SC 69124A) is a highly selective and orally active COX-2 inhibitor, the proagent of Valdecoxib (HY-15762). Parecoxib Sodium is a nonsteroidal anti-inflammatory agent (NSAID) and inhibits prostaglandin (PG) synthesis. Parecoxib Sodium can be used for the relief of acute postoperative pain and symptoms of chronic inflammatory conditions such as osteoarthritis and rheumatoid arthritis in vivo .

HY-B0890R

Zomepirac sodium salt (Standard) McN-2783-21-98 (Standard)	PGE synthase Reference Standards	Neurological Disease Inflammation/Immunology
Zomepirac sodium salt (Standard) is the analytical standard of Zomepirac sodium salt (HY-B0890). This product is intended for research and analytical applications. Zomepirac sodium salt (McN-2783-21-98) is an orally active prostaglandin synthetase inhibitor. Zomepirac sodium salt blocks prostaglandin synthesis and inhibits Collagen (HY-P72147)- or Epinephrine (HY-B0447)-induced platelet aggregation. Zomepirac sodium salt can be used for the research of postoperative pain and osteoarthritis .

HY-17474S1

Parecoxib-d5 SC 69124-d₅	Isotope-Labeled Compounds COX	Inflammation/Immunology Cancer
Parecoxib-d₅ (SC 69124-d₅) is deuterium labeled Parecoxib. Parecoxib (SC 69124) is a highly selective and orally active COX-2 inhibitor, the proagent of Valdecoxib (HY-15762). Parecoxib Sodium is a nonsteroidal anti-inflammatory agent (NSAID) and inhibits prostaglandin (PG) synthesis. Parecoxib can be used for the relief of acute postoperative pain and symptoms of chronic inflammatory conditions such as osteoarthritis and rheumatoid arthritis in vivo.

HY-100516R

Cimicoxib (Standard) UR-8880 (Standard)	Reference Standards Cytochrome P450 COX	Inflammation/Immunology
Cimicoxib (Standard) is the analytical standard of Cimicoxib. This product is intended for research and analytical applications. Cimicoxib (UR-8880) is an orally active, blood-brain barrier-permeable COX-2 inhibitor that also exerts targeted inhibition on CYP2D15. It has an IC₅₀ of 66 nM against hCOX-2, an IC₅₀ of 1.6 μM against canine CYP2D15, and an IC₅₀ of 0.056 μM against feline CYP2D15. By inhibiting the COX-2 pathway to reduce the production of thromboxane B2 and prostaglandin E2, Cimicoxib exerts antipyretic, anti-inflammatory and analgesic effects. Cimicoxib is metabolized by CYP2D15 to form demethyl-cimicoxib, undergoes glucuronidation via UDP-glucuronosyltransferases, and exhibits biphasic elimination kinetics in beagle dogs. Cimicoxib is widely used in studies of inflammatory diseases, osteoarthritis, and perioperative pain associated with orthopedic or soft tissue surgeries .

HY-B1456AR

Fenoprofen (Standard) LILLY-53858 (Standard)	Reference Standards COX Melanocortin Receptor ERK	Inflammation/Immunology
Fenoprofen (Standard) (LILLY-53858 (Standard)) is the analytical standard of Fenoprofen (HY-B1456A). This product is intended for research and analytical applications. Fenoprofenc is a nonsteroidal anti-inflammatory agent (NSAID) and inhibits cyclooxygenase (COX). Fenoprofen is a melanocortin receptors (MCRs) positive allosteric modulator (PAM). Fenoprofen also increases ERK1/2 activation in HEK293T cells. Fenoprofen has anti-arthritic activities and can be used for the study of rheumatoid arthritis and osteoarthritis.

HY-182647

LY3023703	PGE synthase	Inflammation/Immunology
LY3023703 is an orally active microsomal prostaglandin E synthase-1 (mPGES-1) inhibitor. LY3023703 inhibits the production of PGE₂. LY3023703 is applicable to research related to inflammatory diseases and osteoarthritis pain .

HY-108519R

AS1892802 (Standard)	Reference Standards ROCK	Neurological Disease
AS1892802 (Standard) is the analytical standard of AS1892802 (HY-108519). This product is intended for research and analytical applications. AS1892802 is a potent, orally active, and highly selective inhibitor of ROCK. The onset of antinociceptive effect of AS1892802 is as fast as those of Tramadol and Diclofenac. AS1892802 did not induce gastric irritation or abnormal behavior. AS1892802 is an attractive analgesic profile for the research of severe osteoarthritis pain .

HY-182783

JNJ-10450232 NTM-006	Adenosine Receptor	Neurological Disease Inflammation/Immunology
NTM-006 is a selective and brain-penetrant adenosine A3 receptor (A3AR) agonist. NTM-006 selectively interacts with adenosine A3AR via π-π stacking with Phe168 and π-alkyl interactions receptor residues. NTM-006 inhibits Acetic acid (HY-Y0319)-induced writhing responses in mice. NTM-006 can be used for the research of chronic neuropathic pain, cancer-related pain, osteoarthritis-associated pain .

HY-P11629

KBP-336	Amylin Receptor CGRP Receptor	Neurological Disease Metabolic Disease Inflammation/Immunology
KBP-336 is a dual amylin and calcitonin receptor agonist (DACRA). KBP-336 exhibits antidiabetic and insulin-sensitizing properties, improves glucose levels, spatial learning, and memory in diabetic rats, and reduces blood glucose. KBP-336 also alleviates pain-like symptoms in osteoarthritis rats. KBP-336 also promotes weight and fat reduction. KBP-336 is useful for research on diabetes, obesity, and arthritis .

HY-165459

KJM429 MK-056	TRP Channel	Infection Inflammation/Immunology
KJM429 (MK-056) is a high-affinity ligand for the rat vanilloid receptor rTRPV1 (K_i=30-63 nM) with a unique dual regulatory function. KJM429 acts as a competitive antagonist to inhibit TRPV1 receptor activation induced by Capsaicin (HY-10448), resiniferatoxin, thermal stimulation and weak acid (pH 6.0), and switches to a TRPV1 agonist under strong acid conditions (pH<5.5). KJM429 effectively blocks calcium influx induced by Capsaicin and partial thermal stimulation, and triggers calcium uptake under low pH conditions, with minimal effects on non-TRPV1-mediated calcium signaling. KJM429 can be used for research on the mechanisms of pain-related diseases such as postherpetic neuralgia, diabetic neuropathy, cluster headache, osteoarthritis and pruritus .

Cat. No.	상품명	Target	Research Area

HY-P11629

KBP-336	Amylin Receptor CGRP Receptor	Neurological Disease Metabolic Disease Inflammation/Immunology
KBP-336 is a dual amylin and calcitonin receptor agonist (DACRA). KBP-336 exhibits antidiabetic and insulin-sensitizing properties, improves glucose levels, spatial learning, and memory in diabetic rats, and reduces blood glucose. KBP-336 also alleviates pain-like symptoms in osteoarthritis rats. KBP-336 also promotes weight and fat reduction. KBP-336 is useful for research on diabetes, obesity, and arthritis .

Cat. No.	상품명	Target	Research Area	Image

HY-P99221

Tanezumab RN-624; PF 4383119	Trk Receptor	Neurological Disease Inflammation/Immunology Cancer
Tanezumab (RN-624) is a humanized anti-NGF mAb with high affinity and specificity. Tanezumab blocks NGF binding to its receptors, p75 and TrkA, in the peripheral nervous system. Tanezumab can be used in studies of acute and chronic pain such as osteoarthritis, knee and neuralgia, as well as post-herpetic neuralgia .

HY-P99297

Bedinvetmab ZTS-00508841	Trk Receptor	Inflammation/Immunology
Bedinvetmab (ZTS-00508841) is a canine monoclonal antibody (mAb) targeting nerve growth factor (NGF). Bedinvetmab inhibits NGF interaction with tropomyosin receptor kinase A (trkA) and p75 neurotrophin receptor (p75NTR) receptors. Bedinvetmab can be used for the research of osteoarthritis pain in dogs .

HY-P99627

Frunevetmab NV-02; PG110; ABT-110	Trk Receptor	Inflammation/Immunology
Frunevetmab (NV-02) is a felinized anti-nerve growth factor (NGF) monoclonal antibody with a K_d of 20 pM. Frunevetmab can effectively decrease osteoarthritis (OA) pain in cats .

HY-P990071

Fepixnebart LY-3016859	EGFR	Neurological Disease Metabolic Disease Inflammation/Immunology
Fepixnebart (LY3016859) is a humanized monoclonal hIgG4 antibody, which binds and neutralizes only TGFα and epiregulin with high affinity. Fepixnebart can be used for the study of diabetic nephropathy and broad-spectrum chronic pain, including diabetic peripheral neuropathic pain (DPNP), signs and symptoms of osteoarthritis (OA), and chronic low back pain (CLBP) .

HY-P991324

MEDI-7352	Trk Receptor TNF Receptor	Inflammation/Immunology
MEDI-7352 is a human bispecific antibody (bsAb) targeting NGF/bNGF & TNF. MEDI-7352 can be used in osteoarthritis (OA) pain research .

HY-P99748

Nadecnemab	TGF-β Receptor	Inflammation/Immunology
Nadecnemab is an IgG4κ antibody targeting to GFRA3, glial cell derived neurotrophic factor family receptor alpha 3. Nadecnemab can be used for research of osteoarthritis of the knee/pain .

Cat. No.	상품명	Chemical Structure

HY-17474S

Parecoxib-d3

Parecoxib-d3 is the deuterium labeled Parecoxib. Parecoxib (SC 69124) is a highly selective and orally active COX-2 inhibitor, the proagent of Valdecoxib (HY-15762). Parecoxib Sodium is a nonsteroidal anti-inflammatory agent (NSAID) and inhibits prostaglandin (PG) synthesis. Parecoxib can be used for the relief of acute postoperative pain and symptoms of chronic inflammatory conditions such as osteoarthritis and rheumatoid arthritis in vivo.

HY-17474AS

Parecoxib-d5 sodium

Parecoxib-d₅ sodium is the deuterium labeled Parecoxib sodium. Parecoxib Sodium (SC 69124A) is a highly selective and orally active COX-2 inhibitor, the proagent of Valdecoxib (HY-15762). Parecoxib Sodium is a nonsteroidal anti-inflammatory agent (NSAID) and inhibits prostaglandin (PG) synthesis. Parecoxib Sodium can be used for the relief of acute postoperative pain and symptoms of chronic inflammatory conditions such as osteoarthritis and rheumatoid arthritis in vivo .

HY-17474S1

Parecoxib-d5

Parecoxib-d₅ (SC 69124-d₅) is deuterium labeled Parecoxib. Parecoxib (SC 69124) is a highly selective and orally active COX-2 inhibitor, the proagent of Valdecoxib (HY-15762). Parecoxib Sodium is a nonsteroidal anti-inflammatory agent (NSAID) and inhibits prostaglandin (PG) synthesis. Parecoxib can be used for the relief of acute postoperative pain and symptoms of chronic inflammatory conditions such as osteoarthritis and rheumatoid arthritis in vivo.

온라인 문의

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
호칭			Country or Region *
고객명 *			회사명 *
Department *
메일주소 *			상품명 *
Cat. No.			Requested quantity *
전화번호 *
비고

온라인 문의

Inquiry Information

상품명:
Cat. No.:
수량:
MCE Japan Authorized Agent: